Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2700 of 3499 entries
View as:

Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families

Phase: N/A Priority: Normal
NCT ID: NCT00393224 Org: User:
Start: 07/05/05 End: 06/02/20 Due: 06/02/21

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00706992 Org: User:
Start: 06/30/08 End: 11/30/12 Due: 11/30/13

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01249430 Org: User:
Start: 01/20/11 End: 05/24/13 Due: 05/24/14

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Phase: N/A Priority: Normal
NCT ID: NCT03436745 Org: User:
Start: 01/22/19 End: 01/30/24 Due: 01/30/25

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

Phase: N/A Priority: Normal
NCT ID: NCT02381535 Org: User:
Start: 10/22/15 End: 04/24/20 Due: 04/24/21

Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00923949 Org: User:
Start: 08/31/08 End: 03/31/10 Due: 03/31/11

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00019084 Org: User:
Start: 02/29/96 End: 05/31/03 Due: 05/31/04

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04034927 Org: User:
Start: 12/04/19 End: 02/21/26 Due: 02/21/27

NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data

Phase: N/A Priority: Normal
NCT ID: NCT04750915 Org: User:
Start: 02/09/21 End: 12/31/50 Due: 12/31/51

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00942331 Org: User:
Start: 07/15/09 End: 06/15/21 Due: 06/15/22

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00878163 Org: User:
Start: 03/31/09 End: 03/06/26 Due: 03/06/27

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01258998 Org: User:
Start: 12/31/10 End: 08/31/15 Due: 08/31/16

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05276973 Org: User:
Start: 09/08/22 End: 02/26/26 Due: 02/26/27

Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China

Phase: N/A Priority: Normal
NCT ID: NCT02586532 Org: User:
Start: 10/19/15 End: 06/05/20 Due: 06/05/21

Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research

Phase: N/A Priority: Normal
NCT ID: NCT01851382 Org: User:
Start: 05/15/13 End: 02/12/15 Due: 02/12/16

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00093418 Org: User:
Start: 09/30/04 End: - Due: -

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Phase: N/A Priority: Normal
NCT ID: NCT04817241 Org: User:
Start: 02/10/22 End: 10/25/25 Due: 10/25/26

Smokefree.Gov Website in Helping United States Federal Employees Quit Smoking

Phase: N/A Priority: Normal
NCT ID: NCT00245076 Org: User:
Start: 04/30/05 End: 10/31/07 Due: 10/31/08

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Phase: N/A Priority: Normal
NCT ID: NCT00030667 Org: User:
Start: 05/31/02 End: 12/31/05 Due: 12/31/06

Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00049166 Org: User:
Start: 10/31/02 End: - Due: -

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00723255 Org: User:
Start: 09/30/08 End: 01/25/16 Due: 01/25/17

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT00076752 Org: User:
Start: 01/30/04 End: 10/15/13 Due: 10/15/14

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Phase: N/A Priority: Normal
NCT ID: NCT00520130 Org: User:
Start: 10/30/07 End: 12/31/18 Due: 12/31/19

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00665470 Org: User:
Start: 04/30/08 End: 04/30/12 Due: 04/30/13

Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00118235 Org: User:
Start: 12/31/04 End: 07/31/11 Due: 07/31/12